Chargement...

Robocath in a few words

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer thanks to reliable technologies, while complementing manual interventions.
R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed.
R-One™ is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One™ is compatible with
market-leading devices and cath labs.
In a prospective, randomized, controlled pre-clinical trial, R-One™ demonstrated safety and efficacy as it achieved 100% technical procedure success and no MACE (Major adverse cardiovascular events). R-One™ received the CE marking in February 2019 and started its clinical application in September 2019. Currently R-One™ is available in Europe and Africa.
Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all.
Based in Rouen, France, Robocath has more than 50 employees.

History

2009
Company foundation
2013
First in vivo tests
2014
ISO 13485 certification granted
2015
Industrial prototype
2017
Safety-Efficacy study
2019
R-One pre-launch

Robocath in the world

19 Rue Marie Curie, Rouen, France
50 Milk Street, Boston, Massachusetts, États-Unis

Management

Philippe BENCTEUX

Founder & President
Learn more
A doctor of medicine and a graduate of the 'Healthcare Industry Strategy and Management' program at ESSEC Business School, Philippe Bencteux has over twenty years of experience in vascular imaging. A trained neuro-radiologist, he founded Robocath in 2009 on the basis of the promising preliminary research carried out in collaboration with two engineering schools. He has since contributed his expertise in the medical sector to the company and is actively involved in the conception of new robotics solutions.

Lucien GOFFART

CEO
Learn more
Holding a master’s degree in Business, Lucien Goffart started his career in 1999 at Johnson & Johnson Inc. Then, he joined Abbott before holding different positions at Volcano company between 2004 and 2011. From 2012 to 2014, he held different executive positions at Stentys and Mitralgin. Last four years, he served Boston Scientific as Business Unit Manager France. In the meanwhile, he was Board member of several companies from the Medtech industry such as Opsens Medical. Since 2019, he is Board member of Electroducer and was appointed CEO of Robocath in September.

Bruno FOURNIER

CTO
Learn more
Bruno Fournier is a trained engineer (Supélec) and Doctor of Science (Université Paris VI), with strong R&D experience in the healthcare sector. He led the development of products with high added value in several fields (ultrasound, bone density measurement, respiratory support, etc.). Passionate about new medical technologies, he joined Robocath in 2012 after management roles with the Air Liquide Groupe and his time as Director of R&D at one of Getinge Group subsidiary from 2006 to 2012.

Sarah ANKRI

CFO
Learn more
Holding a master’s degree in Economy & Management, Sarah started her career in 2007, working on fund raising, acquisitions, and legal audit assignments at EY. Prior to join Robocath, she was CFO at Theraclion (Medtech) and Lysogene (Biotech) where she successfully led IPOs in 2014 and 2017. She was awarded by Les Echos as “Next leaders” in Finance category in 2017. She was a Board member of France Biotech between 2013 and 2015 and president of the Corporate Finance commission until 2018. In March 2021, she was appointed CFO of Robocath.

Strategic Committee

Jonathan CHEN

MICROPORT
Learn more
Mr. Jonathan Chen is the Chief International Business Officer of the MicroPort Scientific Corporation, Chairperson of Intercontinental CRM Committee, Co-Chairperson of InterContinental Orthopedics Committee and a member of the General Management Committee of MicroPort. Prior to current positions, he has served as the Executive Vice President of International Operations and Investor Relations of the Company. Mr. Chen's primary responsibilities include growing the company's International business in markets of the U.S, Europe, Asia Pacific and Latin America. Mr. Chen has over 23 years of experience in the medical device industry. Prior to joining the Company, Mr. Chen worked for Angiotech Pharmaceuticals, Inc. for 6 years, where he was Senior Vice President of Business Development & Financial Strategy. Prior to joining Angiotech, Mr. Chen was a life sciences investment banker for Credit Suisse and Alex. Brown & Sons.

Pierre-Emmanuel STRUYVEN

SUPERNOVA INVEST
Learn more
Newly created by the CEA Investissement seasoned funds management team, CEA and Amundi, Supernova Invest is specialized in deep-tech venture capital in life sciences, energy and industry (electronics, advanced materials, instruments…).

Haitong Wang

ZHEJIANG SILK ROAD FUND
Learn more
Mr. Haitong Wang is managing partner at Zhejiang Silk Road Fund. Zhejiang Silk Road Fund is a Chinese private equity fund focusing on cross-border investments across various sectors, including healthcare, advanced manufacturing, TMT, and consumer. The fund is managed by Zhejiang United Investment Group (‘ZUIG’), an investment firm backed by eight Zhejiang-based entrepreneurs. ZUIG currently has about RMB 12 billion ($1.7b) assets under management and has offices in Hangzhou, Shanghai, Hong Kong, and Shenzhen.

Jean-Marc BUCHET

NCI
Learn more
An historic investor in Robocath (since 2013), NCI is a major player in capital investment in Normandy.

Bruno GUICHEUX

GO CAPITAL
Learn more
An historic investor in Robocath (since 2013), GO CAPITAL is an investment fund management company that favors companies with high growth potential in the fields of healthcare, technology (hardware and software), digital and innovative services.

Chao (Alex) HE

MICROPORT
Learn more
Pr. Chao He (Alex) is general manager of Medbot, a MicroPort’s robotics subsidiary. Founded in 1998 in Shanghai (China) with the common belief that advancements in medical technology can transform patients’ lives, MicroPort is a global leading developer, manufacturer and operator focusing on minimally invasive intervention products for the treatment of vascular diseases and pathological changes. Over the last two decades, MicroPort has taken important steps towards fulfilling its mission of providing access to the best means of prolonging and reshaping lives and today provides over 300 devices and technologies, currently approved for use in nearly 10,000 hospitals worldwide. At MicroPort innovation is part of our DNA¸ not only in the treatments and services we develop but also in the way we foster innovation. With a vast global footprint of R&D and manufacturing sites (Shanghai; Memphis (TN) in the United States; Clamart in France; Saluggia in Italy; Santo Domingo in Dominican Republic), a strong focus on technology innovation with over 4,000 patent applications, and a global workforce of over 7,000 employees, MicroPort is committed to its vision of building a People Centric Consortium of companies focused on Emerging Medical Technologies.

Chantal Le Chat

Independent Member
Learn more
Chantal Le Chat joined GE Healthcare in 1985 as an engineer. She then held various leadership roles in Engineering within the XRays tubes as well as the Vascular organization based in Buc (France) or Milwaukee (Wisconsin, US). In 2000, she moved to the Service organization, leading Service Operations for EMEA before becoming in 2002 the Service GM for France-Belgium-Luxemburg. In this role, she drove customer satisfaction, operational excellence and profitable growth. In 2005, Chantal was promoted to EMEA Product GM for Surgery, Interventional & XRays and successfully developed the business for five years. In 2010, she became the Global Segment GM for Premium Angiography and Hybrid-OR. In this role, she drove market creation as well as introduced disruptive products and applications such as the Discovery IGS 7 platform. In mid-14, she expanded her role to cover also the CardioVascular segment and became the Global GM for Interventional. Chantal holds an Engineering degree in Physics from the “Ecole Supérieure de Physique et Chimie Industrielles” (ESPCI) and a Master in Medical Instrumentations, Paris France – 1985.

Medical Advisory Board

Professeur A. CRIBIER

Former Chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI
Learn more
Professor of medicine and former chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI (Transcatheter Aortic Valve Implantation) procedure, a breakthrough, less invasive interventional treatment for structural heart diseases. Since its creation, the device has been implanted in thousands of patients around the world. He is the author of more than 600 publications and has received several major international medical and scientific awards.

Docteur J. FAJADET

Co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse (France), co-director of EuroPCR congress
Learn more
• co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse, co-director of EuroPCR, one of the most important interventional cardiology congresses in the world. Director of the EAPCI, (European Association of Percutaneous Cardiovascular Interventions) between 2011 and 2014. He is the author of numerous publications and holds several major awards.

Docteur A. CREMONESI

Head of the Villa Maria hospital cardiovascular department in Bologna (Italy) and active member of EuroPCR Board
Learn more
Head of the Villa Maria hospital cardiovascular department in Bologna (Italy) for the last 25 years, published many interventional cardiology and peripheral vascular papers. From 2011 to 2013, he was president of the Italian society of interventional cardiology. He has for many years been an active member of the PCR board and received several awards in recognition of his achievements.

Professeur G. STONE

Director of cardiovascular research and training at the Center for Interventional Therapy at Colombia University Medical Center and at the Cardiovascular Research Foundation
Learn more
professor of medicine and director of cardiovascular research and training at the Center for Interventional Therapy at Colombia University Medical Center and at the Cardiovascular Research Foundation, both in New York. Regularly engaged in clinical research and professional education, he has led and published more than 2,000 manuscripts and abstracts and has received several major awards for his work. He is director of the TCT Congress (Transcatheter Cardiovascular Therapeutics), one of the largest interventional cardiology gatherings in the world.

Professor E. DURAND

Rouen University Hospital
Learn more

Professor R. SABATIER

Caen University Hospital
Learn more

Professor M. HAUDE

Neuss Clinic - Neuss Germany
Learn more
Pr. Haude has been head physician of the Medical Clinic I at the Clinic Neuss for 13 years and is thus also in charge of cardiology and of their cardiac catheter labs. In addition, Professor Haude has been involved in interventional cardiology for 31 years and has been past chairman of the Working Group on Interventional Cardiology (AGIK) at the German Society of Cardiology , PCR and ESC board member and EAPCI president from 2016 to 2018. He currently is an EAPCI board member, Pr. Haude has published more than 300 scientific articles.

Doctor F. LORGAT

Netcare Christiaan Barnard Memorial Hospital - Cape Town, South Africa
Learn more
Dr. Lorgat is an interventional cardiologist at Christiaan Barnard Memorial Hospital since 1998. As one of the first users of a robotic system for electrophysiology, Dr. Lorgat has performed more than 1,600 procedures with this robotic assistance over a period of 6 years and is an active research contributor in this field.

Awards

Rated as fourth Medical French Start-up
by Forbes Magazine
Winner of the TechInnov Award 2015
Nominee for "Trophée de l'Avenir" 2018
by Europe 1
Nominee for French Start-up of the year 2018
by EY

Partners